A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)
Limaye S, Riley S, Zhao S, O’Neill A, Posner M, Adkins D, Jaffa Z, Clark J, Haddad R. A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN). Oral Oncology 2013, 49: 835-841. PMID: 23727257, DOI: 10.1016/j.oraloncology.2013.04.010.Peer-Reviewed Original ResearchConceptsSquamous cell carcinoma of head and neckMetastatic squamous cell carcinoma of head and neckProgression free survivalPhase II study of docetaxelDisease control rateDuration of responseStudy of docetaxelDocetaxel armOverall survivalResponse rateCombination armCarcinoma of head and neckMedian progression free survivalMulticenter phase II studyRandomized phase II studyMetastatic squamous cell carcinomaPlatinum based therapyToxicity of docetaxelHead and neckFree survivalOpen-labelAnalyzed patientsChemotherapeutic optionsPalliative treatmentControl rate
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply